Valuation Update With 7 Day Price Move • Jun 08
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to ₩1,156, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 56% over the past three years. Buy Or Sell Opportunity • Apr 29
Now 23% overvalued Over the last 90 days, the stock has fallen 5.1% to ₩2,145. The fair value is estimated to be ₩1,747, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.2% over the last 3 years. Meanwhile, the company has become profitable. Buy Or Sell Opportunity • Apr 01
Now 21% overvalued Over the last 90 days, the stock has fallen 3.7% to ₩2,055. The fair value is estimated to be ₩1,704, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.2% over the last 3 years. Meanwhile, the company has become profitable. Duyuru • Mar 07
WAPS Co., Ltd, Annual General Meeting, Mar 26, 2026 WAPS Co., Ltd, Annual General Meeting, Mar 26, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 45, centum dong-ro, haewoondae-gu, busan South Korea Buy Or Sell Opportunity • Mar 03
Now 24% undervalued Over the last 90 days, the stock has risen 53% to ₩2,430. The fair value is estimated to be ₩3,185, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.0% over the last 3 years. Meanwhile, the company has become profitable. Buy Or Sell Opportunity • Feb 10
Now 20% undervalued Over the last 90 days, the stock has risen 96% to ₩2,540. The fair value is estimated to be ₩3,184, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.0% over the last 3 years. Meanwhile, the company has become profitable. Valuation Update With 7 Day Price Move • Feb 06
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₩2,685, the stock trades at a trailing P/E ratio of 12.5x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 15% over the past three years. Buy Or Sell Opportunity • Jan 22
Now 21% undervalued Over the last 90 days, the stock has risen 71% to ₩2,365. The fair value is estimated to be ₩2,976, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.0% over the last 3 years. Meanwhile, the company has become profitable. Valuation Update With 7 Day Price Move • Jan 20
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩2,385, the stock trades at a trailing P/E ratio of 11.1x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 28% over the past three years. New Risk • Dec 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩30.4b market cap, or US$20.5m). Valuation Update With 7 Day Price Move • Dec 17
Investor sentiment improves as stock rises 30% After last week's 30% share price gain to ₩2,115, the stock trades at a trailing P/E ratio of 9.9x. Average trailing P/E is 11x in the Chemicals industry in South Korea. Total loss to shareholders of 34% over the past three years. Valuation Update With 7 Day Price Move • Nov 19
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩1,517, the stock trades at a trailing P/E ratio of 12x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 44% over the past three years. New Risk • May 22
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 3.8% Last year net profit margin: 6.0% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Profit margins are more than 30% lower than last year (3.8% net profit margin). Market cap is less than US$100m (₩19.8b market cap, or US$14.4m). Valuation Update With 7 Day Price Move • Apr 02
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₩1,370, the stock trades at a trailing P/E ratio of 16.5x. Average trailing P/E is 10x in the Chemicals industry in South Korea. Total loss to shareholders of 72% over the past three years. Duyuru • Mar 07
WAPS Co., Ltd, Annual General Meeting, Mar 26, 2025 WAPS Co., Ltd, Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 45, centum dong-ro, haewoondae-gu, busan South Korea New Risk • Dec 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩21.3b market cap, or US$14.8m). New Risk • Dec 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩16.4b market cap, or US$11.4m). Valuation Update With 7 Day Price Move • Nov 14
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₩1,103, the stock trades at a trailing P/E ratio of 6.7x. Average trailing P/E is 9x in the Chemicals industry in South Korea. Total loss to shareholders of 87% over the past three years. New Risk • Mar 27
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 2.2x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.2x net interest cover). Minor Risk Market cap is less than US$100m (₩25.2b market cap, or US$18.7m). Buying Opportunity • May 12
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 23%. The fair value is estimated to be ₩3,074, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.8% over the last 3 years. Meanwhile, the company became loss making. Buying Opportunity • Apr 24
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 27%. The fair value is estimated to be ₩3,045, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.8% over the last 3 years. Meanwhile, the company became loss making. Valuation Update With 7 Day Price Move • Jun 23
Investor sentiment deteriorated over the past week After last week's 19% share price decline to ₩2,900, the stock trades at a trailing P/E ratio of 72.7x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 22% over the past three years. Valuation Update With 7 Day Price Move • Mar 08
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₩3,835, the stock trades at a trailing P/E ratio of 36.4x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total returns to shareholders of 72% over the past three years. Valuation Update With 7 Day Price Move • Feb 14
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₩4,900, the stock trades at a trailing P/E ratio of 46.5x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total returns to shareholders of 83% over the past three years. Buying Opportunity • Jan 24
Now 27% undervalued Over the last 90 days, the stock is up 43%. The fair value is estimated to be ₩8,627, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.0% per annum over the last 3 years. The company has become profitable over the last year. Buying Opportunity • Jan 24
Now 27% undervalued Over the last 90 days, the stock is up 43%. The fair value is estimated to be ₩8,627, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.0% per annum over the last 3 years. The company has become profitable over the last year. Valuation Update With 7 Day Price Move • Jan 21
Investor sentiment improved over the past week After last week's 26% share price gain to ₩6,960, the stock trades at a trailing P/E ratio of 66.1x. Average trailing P/E is 17x in the Chemicals industry in South Korea. Total returns to shareholders of 211% over the past three years. Valuation Update With 7 Day Price Move • Dec 20
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₩4,870, the stock trades at a trailing P/E ratio of 46.2x. Average trailing P/E is 17x in the Chemicals industry in South Korea. Total returns to shareholders of 147% over the past three years. Valuation Update With 7 Day Price Move • Nov 30
Investor sentiment deteriorated over the past week After last week's 21% share price decline to ₩5,290, the stock trades at a trailing P/E ratio of 50.2x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total returns to shareholders of 144% over the past three years. Is New 90 Day High Low • Feb 08
New 90-day high: ₩2,075 The company is up 5.0% from its price of ₩1,985 on 10 November 2020. The South Korean market is up 25% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 28% over the same period. Is New 90 Day High Low • Jan 21
New 90-day high: ₩2,010 The company is up 7.0% from its price of ₩1,885 on 23 October 2020. The South Korean market is up 31% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 39% over the same period.